Sign inCreate account

Report workspace tools

NCT00605059TERMINATEDanonymous

Evaluation of [123I] AV94 and SPECT as a Marker of Beta-amyloid Protein Deposition in Subjects With Alzheimer Disease in Comparison to Healthy Subjects

Sponsor

Source record

Institute for Neurodegenerative Disorders

Phase

Source record

PHASE1

Modality

AI-normalized

small molecule

Target

AI-normalized

Beta-amyloid protein deposition in Alzheimer's disease

Indication / condition

AI-normalized

Alzheimer Disease

Intervention

Source record

[123I]AV94

Source & freshness

Source record

NCT ID

NCT00605059

Original source

ClinicalTrials.gov

Source last updated

Oct 06, 2010

Ingested at

May 23, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT00605059

Title

Evaluation of [123I] AV94 and SPECT as a Marker of Beta-amyloid Protein Deposition in Subjects With Alzheimer Disease in Comparison to Healthy Subjects

Sponsor

Institute for Neurodegenerative Disorders

Status

TERMINATED

Phase

PHASE1

Condition raw

Alzheimer Disease

Condition normalized

Alzheimer Disease

Modality raw

Alzheimer Disease

Modality normalized

small molecule

Target raw

Beta-amyloid protein deposition in Alzheimer's disease

Target normalized

Beta-amyloid protein deposition in Alzheimer's disease

Interventions

[123I]AV94

Public preview

Source record

The clinical trial aimed to evaluate [123I] AV94 as a potential imaging biomarker for beta-amyloid burden in Alzheimer's disease using SPECT imaging. Conducted by the Institute for Neurodegenerative Disorders, the study involved 20 Alzheimer's patients and 10 healthy controls to assess the uptake and washout of the imaging agent.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Evaluation of [123I] AV94 and SPECT as a Marker of Beta-amyloid Protein Deposition in Subjects With Alzheimer Disease in Comparison to Healthy Subjects

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT00605059

Status

TERMINATED

Phase

PHASE1

Sponsor

Institute for Neurodegenerative Disorders

Executive brief

Investment-Ready Snapshot

The clinical trial aimed to evaluate [123I] AV94 as a potential imaging biomarker for beta-amyloid burden in Alzheimer's disease using SPECT imaging. Conducted by the Institute for Neurodegenerative Disorders, the study involved 20 Alzheimer's patients and 10 healthy controls to assess the uptake and washout of the imaging agent.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedOct 06, 2010
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT00605059

Indication

Alzheimer Disease

Modality

small molecule

Target

Beta-amyloid protein deposition in Alzheimer's disease

Intervention

[123I]AV94

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.